Skip to main content
. 2024 Apr 5;13(2):115–122. doi: 10.1097/eus.0000000000000052

Table 3.

Clinical characteristics and EUS-TA results of nonmalignant lesions.

Variables Total
n = 108
No malignancy
n = 28
Other than no malignancy
n = 80
P
Median age (range),a y 63 (29–86) 63 (30–79) 61 (29–86) 0.93
Male sex, n (%) 59 (54.6) 13 (46.4) 46 (57.5) 0.29
Median tumor size (range), mm 8 (2.5–10) 7.45 (2.5–9.8) 8 (2.5–10) 0.49
Tumor location, n (%) 0.069
 Pancreatic head 34 (31.5) 13 (46.4) 21 (25.9)
 Pancreatic body or tail 74 (68.5) 15 (53.6) 59 (74.1)
Needle type, n (%) 0.77
  EUS-FNA 63 (58.3) 17 (60.7) 46 (57.5)
  EUS-FNB 45 (41.7) 11 (39.3) 34 (42.5)
Needle size, n (%) 0.35
 19-Gauge or 22-gauge 102 (94.4) 26 (92.9) 76 (95)
 25-Gauge 6 (5.6) 2 (7.1) 4 (5)
Mean no. of passes for EUS-TA (IQR) 3 (2–4) 3.9 (2–4) 3.1 (2–4) 0.86

a Age at which EUS-TA was performed.

EUS-FNA/FNB: EUS fine-needle aspiration/biopsy; EUS-TA: EUS tissue acquisition; IQR: Interquartile range.